David J. McLachlan

HearUSA, Inc. distributes audio-logical products and provides hearing impaired services. The company provides hearing care to patients primarily through its company-owned hearing care centers, which offers a complete range of quality hearing aids, with an emphasis on the latest digital technology. It provides hearing care to patients whose health insurance and Managed-care organizations have contracted with the company for such care and to retail self-pay patients. It offers hearing related products, such as batteries, hearing aid accessories and assistive listening devices online through its website. The Company operates two business segments: Center and Network segments. The Center segment offers patients a complete range of hearing care services and products, including diagnostic audiologic testing, the latest technology in hearing aids and assistive listening devices to improve their quality of life. The Network segment sponsors a network of credentialed audiology providers that supports hearing benefit programs with employer groups, health insurers and benefit sponsors. Through the network, the company can pursue national hearing care contracts and offer managed hearing benefits in areas outside of the company-owned center markets. HearUSA was founded on April 11, 1986 by Paul A Brown and is headquartered in West Palm Beach, FL.

Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA.

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Adams-Russell Co., Inc. was a manufacturer of microwave equipment and CATV systems. In 1988, the company was acquired by Cablevision Systems Corporation. The company was located in Waltham, MA.